Olvera CS

Language: Spanish
References: 6
Page: 106-108
PDF size: 43.36 Kb.

ABSTRACT

Treatment of chronic heart failure still needs to be improved. Blockade of ET-1 and TNF-α, as well as the combined inhibition of ACE and NE have demonstrated limited benefits, thus other strategies continue being evaluated. This article reviews current concepts regarding the blockade of arginine vasopressin receptors (AVP) and the selective inhibition of matrix metalloproteinases (MMPs). Results with AVP blockade in humans have been encouraging, whereas inhibitors of MMPs continue under preclinical experimental phases and are controversial.

REFERENCES

1. Goldsmith SR: Vasopressin, a therapeutic target in congestive heart failure? J Cardiol Fail 1999; 5: 347-356.

2. Schier RW, Abraham TW: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-584.

3. Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM: Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition. Cardiovasc Res 2002; 54: 51-57.

4. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al: Acute hemodynamic effects of Conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423.

5. Spinale FG, Coker ML, Bond BR, Zellner JL: Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potentia l therapeutic target. Cardiovasc Res 2000; 46: 225-228.

6. Peterson JT, Hallak H, Johnston L, Li H, O’Brien PM, Sliskovic DR, et al: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in rat model of progressive heart failure. Circulation 2001; 103: 2303-2309.